Health Care·Biotechnology·$8.1B
Cytokinetics Inc is a biotechnology company focused on developing muscle-targeted therapies for people with serious diseases. As part of the health care sector, its innovations could significantly impact treatments for conditions like heart failure and muscle disorders, making it a key player in the biotech industry.
EPS
Earnings per share is a critical indicator of the company's profitability and financial health.
Revenue
Revenue figures will provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
25%
Avg EPS Surprise
-12.09%
Avg Stock Reaction
+0.91%
In Q4-2025, Cytokinetics reported an EPS of $-1.50, slightly missing analyst expectations. The stock reacted positively, gaining 2.70% the following day.
Management Promises & Guidance
Analysts expect Cytokinetics to report a loss of $-1.65 per share on revenues of $9 million for Q1-2026. The company has shown mixed performance in previous quarters, leading to cautious sentiment.
Bull Case
If Cytokinetics can exceed revenue expectations and narrow its losses, it may signal stronger demand for its therapies and boost investor confidence.
Bear Case
Conversely, if the company reports a wider loss or lower revenue, it could raise concerns about its product pipeline and market position.
EPS
$-1.65Earnings per share is a critical indicator of the company's profitability and financial health.
Revenue
$9MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will Cytokinetics report revenue above the consensus estimate of $9 million?
Revenue performance will be closely watched as it indicates market demand and the effectiveness of the company's sales strategies.
Q2
How will the company address its expected loss of $-1.65 per share?
Investors will want to hear management's plans for reducing losses and improving profitability moving forward.
Why consensus could be wrong
The Street may be underestimating the potential for Cytokinetics to exceed revenue expectations due to recent advancements in its product pipeline.
Supporting Evidence
The company has shown a history of surprising analysts with better-than-expected results in certain quarters.
Recent developments in their therapies could lead to increased demand that is not fully reflected in current estimates.
Key Risk
If the company announces any significant new partnerships or product approvals, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The market is debating the company's ability to grow revenue and manage losses effectively, which will be crucial for its future.
Bull Confirmed If
Revenue exceeding $9 million with a narrower loss than expected would confirm the bull case.
Bear Confirmed If
A loss greater than $-1.65 per share and revenue below $4 million would validate the bear case.
Implied Move
±4.2%
The options market is pricing in a moderate move for the stock following the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Cytokinetics beats expectations, history suggests a potential stock move of +2.39%, confirming positive market sentiment.
In-Line / Cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
Should the company miss earnings expectations, history indicates a potential decline of around +2.39%, raising concerns about its financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026